NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.54 CHF | +0.85% |
|
+1.88% | +6.68% |
| May. 06 | NOVARTIS AG : UBS maintains a Buy rating | ZD |
| May. 02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.51% | 786 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 205 M€ | -.--% | ||
| 0.47% | 0 M€ | +8.02% | ||
| 0.39% | 0 M€ | +18.58% | ||
| 0.37% | 1,166 M€ | +0.26% | - | |
| 0.37% | 607 M€ | +0.05% | - | |
| 0.30% | 0 M€ | +2.74% | - | |
| 0.26% | 0 M€ | +8.19% | - | |
| 0.23% | 0 M€ | +7.83% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.17% | 0 M€ | +5.52% | - | |
| 0.17% | 0 M€ | +5.29% | - | |
| 0.13% | 0 M€ | +3.25% | - | |
| 0.12% | 0 M€ | +2.51% | - | |
| 0.09% | 0 M€ | +3.48% | - | |
| 0.08% | 0 M€ | +2.89% | - | |
| 0.06% | 0 M€ | +0.45% | - | |
| 0.06% | 0 M€ | +0.44% | - |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
99.69
USD
Average target price
108.4
USD
Spread / Average Target
+8.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.68% | 204B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +16.34% | 239B | |
| -9.08% | 198B | |
| +8.62% | 168B | |
| +3.81% | 125B |
- Stock Market
- Equities
- NOVN Stock
- Funds and ETFs Novartis AG